PDT Partners LLC Sells 18,545 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

PDT Partners LLC lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 24.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,735 shares of the biopharmaceutical company's stock after selling 18,545 shares during the quarter. PDT Partners LLC owned about 0.10% of Agios Pharmaceuticals worth $2,521,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in AGIO. Verition Fund Management LLC bought a new stake in Agios Pharmaceuticals during the third quarter worth $315,000. Vestal Point Capital LP bought a new position in Agios Pharmaceuticals during the 3rd quarter worth $33,767,000. Summit Partners Public Asset Management LLC bought a new position in Agios Pharmaceuticals during the 3rd quarter worth $4,520,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Agios Pharmaceuticals by 6.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after purchasing an additional 688 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Agios Pharmaceuticals by 15.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock worth $531,000 after acquiring an additional 1,570 shares during the period.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. This trade represents a 11.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Trading Up 1.2 %

NASDAQ AGIO traded up $0.73 during trading hours on Friday, hitting $59.39. The company's stock had a trading volume of 237,613 shares, compared to its average volume of 729,884. Agios Pharmaceuticals, Inc. has a 52 week low of $20.96 and a 52 week high of $62.58. The company has a market capitalization of $3.39 billion, a PE ratio of 5.23 and a beta of 0.75. The company's 50-day simple moving average is $48.68 and its two-hundred day simple moving average is $45.49.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Royal Bank of Canada reiterated an "outperform" rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Raymond James reiterated an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Scotiabank increased their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a report on Friday, November 1st. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $52.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.